DrugPatentWatch Database Preview

Teva Pharm Company Profile

« Back to Dashboard

What is the competitive landscape for TEVA PHARM, and when can generic versions of TEVA PHARM drugs launch?

TEVA PHARM has two hundred and seventy-two approved drugs.

There are thirty-seven US patents protecting TEVA PHARM drugs. There are thirty-four tentative approvals on TEVA PHARM drugs.

There are four hundred and ninety-six patent family members on TEVA PHARM drugs in forty-two countries and five hundred and twenty-eight supplementary protection certificates in sixteen countries.

Summary for Teva Pharm

International Patents:	496
US Patents:	37
Tradenames:	228
Ingredients:	222
NDAs:	272
Patent Litigation for Teva Pharm:	See patent lawsuits for Teva Pharm
PTAB Cases with Teva Pharm as petitioner:	See PTAB cases with Teva Pharm as petitioner

Drugs and US Patents for Teva Pharm

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms	RIZATRIPTAN BENZOATE	rizatriptan benzoate	TABLET;ORAL	077263-002	Dec 31, 2012	AB	RX	No	No
Teva Pharms Usa	LEVALBUTEROL HYDROCHLORIDE	levalbuterol hydrochloride	SOLUTION;INHALATION	090297-001	Apr 26, 2013	AN	RX	No	No
Teva Pharms Usa	ATAZANAVIR SULFATE	atazanavir sulfate	CAPSULE;ORAL	091673-002	Apr 22, 2014	AB	RX	No	No
Teva Pharm	ARMONAIR RESPICLICK	fluticasone propionate	POWDER;INHALATION	208798-002	Jan 27, 2017		DISCN	Yes	No	9,731,087		Y
Teva Pharms	LEVOCETIRIZINE DIHYDROCHLORIDE	levocetirizine dihydrochloride	TABLET;ORAL	090199-001	Aug 22, 2011	AB	RX	No	No
Teva Pharms	MEGESTROL ACETATE	megestrol acetate	SUSPENSION;ORAL	075681-001	May 5, 2003	AB	RX	No	No
Teva Pharm	ARMONAIR RESPICLICK	fluticasone propionate	POWDER;INHALATION	208798-001	Jan 27, 2017		RX	Yes	No	6,871,646		Y

Expired US Patents for Teva Pharm

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Pharms Usa	COPAXONE	glatiramer acetate	FOR SOLUTION;SUBCUTANEOUS	020622-001	Dec 20, 1996	6,939,539
Teva Pharms Usa	COPAXONE	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	020622-002	Feb 12, 2002	7,199,098
Teva Pharms Usa	COPAXONE	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	020622-003	Jan 28, 2014	6,054,430
Teva Pharms Usa	COPAXONE	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	020622-003	Jan 28, 2014	6,342,476
Teva Pharms Usa	COPAXONE	glatiramer acetate	FOR SOLUTION;SUBCUTANEOUS	020622-001	Dec 20, 1996	6,342,476
Teva Pharms Usa	COPAXONE	glatiramer acetate	FOR SOLUTION;SUBCUTANEOUS	020622-001	Dec 20, 1996	5,981,589
Teva Pharm	AIRDUO RESPICLICK	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-001	Jan 27, 2017	6,446,627

Paragraph IV (Patent) Challenges for TEVA PHARM drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Extended-release Capsule	15 mg and 30 mg		2008-08-11
	Delayed-release Tablets	20 mg		2015-06-03
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-02-26
	for Injection	3.5 mg/vial		2016-10-26
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-01-29

Premature patent expirations for TEVA PHARM

Expiration due to failure to pay maintenance fee

Patent Number	Expiration Date

International Patents for Teva Pharm Drugs

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2016118589
France	2776292
South Korea	100518723
Denmark	2630962
European Patent Office	2630962
Portugal	1443933
European Patent Office	2496294

Supplementary Protection Certificates for Teva Pharm Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1663240	CA 2016 00063	Denmark		PRODUCT NAME: RILPIVIRINHYDROCHLORID OG TENOFOVIRALAFENAMIDFUMARAT; REG. NO/DATE: EU/1/16/1112/001 20160623
0513200	122004000015	Germany		PRODUCT NAME: EMTRIVA-EMTRICITABINE; REGISTRATION NO/DATE: EU/1/03/261/001-003 20031024
1506211	122014000070	Germany		PRODUCT NAME: KOMBINATION VON DAPAGLIFLOZIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, UND METFORMIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, GESCHUETZT DURCH DAS GRUNDPATENT EP 1 506 211; REGISTRATION NO/DATE: EU/1/13/900 20140116
1663240	PA2015037	Lithuania		PRODUCT NAME: RILPIVIRINUM + TENOFOVIRUM DISOPROXILUM + EMTRICITABINUM; REGISTRATION NO/DATE: EU/1/11/737/001 2011 11 28, EU/1/11/737/002 20111128
0273658	C300171	Netherlands		PRODUCT NAME: DULOXETINE EN FARMACEUTISCH AANVAARDBARE ZUURADDITIEZOUTEN DAARVAN, EN IN HET BIJZONDER DULOXETINE HYDROCHLORIDE; NATL REGISTRATION NO/DATE: EU/1/04/280/001-006 20040811
1532149	92128	Luxembourg		PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3, 7-DIHYDROPURIN-2, 6-DION, LES ENANTIOMERES ET LEURS SELS, EN PARTICULIER LA LINAGLIPTINE COMBINEE AVEC DU CHLORHYDRATE DE METFORMINE. LINAGLIPTINE
0480717	SPC/GB98/025	United Kingdom		PRODUCT NAME: MONTELUKAST, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREFERABLY MONTELUKAST SODIUM; REGISTERED: FI 12766 19970825; FI 12767 19970825; UK 00025/0357 19980115; UK 00025/0358 19980115

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Teva
• Teva Branded Pharm
• Teva Parenteral
• Teva Pharm
• Teva Pharms
• Teva Pharms Intl
• Teva Pharms Usa